Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
Atara Biotherapeutics, Inc (Symbol: ATRA) is a pioneering company in the healthcare sector, specializing in the development of transformative therapies for patients combating serious diseases, including cancer, kidney disease, and autoimmune disorders. Founded in August 2012, Atara Biotherapeutics is driven by a mission to provide better treatment options for patients, inspired by Atara Ciechanover, who tragically passed away from cancer in 2012.
The company's research is founded on groundbreaking discoveries related to activin, myostatin, and other growth factors that can alter disease progression. Atara's innovative approach has led to the development of several promising product candidates:
- Pinta 745
- STM 434
- ATA 842
Moreover, Atara Biotherapeutics is collaborating with the prestigious Memorial Sloan Kettering Cancer Center (MSK) to develop three cutting-edge T-cell product candidates:
- Epstein-Barr Virus (EBV)-targeted Cytotoxic T Lymphocytes (CTLs)
- Cytomegalovirus (CMV)-targeted CTLs
- Wilms Tumor 1 (WT1)-targeted CTLs
These T-cell therapies are designed to tackle the underlying mechanisms of various diseases, offering hope for conditions that are currently challenging to treat.
Atara's product pipeline also includes Tab-cel, ATA188, and ATA3219 (CAR T platform). Each of these candidates targets specific mechanisms of disease, aiming to provide effective and innovative treatment solutions.
The company operates within the US healthcare sector, managing its business as a single operating and reportable segment focused on therapeutic development. Atara Biotherapeutics continues to make strides in its mission, marked by recent achievements and partnerships that underscore its commitment to improving patient outcomes.
Stay updated with the latest news and developments from Atara Biotherapeutics to gain insights into their ongoing projects and performance in the stock market.
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, has granted 1,350 restricted stock units to one newly hired employee. The grant was approved by the company's Compensation Committee under the 2018 Inducement Plan, effective February 3, 2025. The stock units will vest over a four-year period, with 25% vesting after the first anniversary and the remaining portions vesting in 12 quarterly installments over the following three years, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
Atara Biotherapeutics (ATRA) announced that the FDA has placed a clinical hold on its active Investigational New Drug (IND) applications for EBVALLO™ (tabelecleucel) and ATA3219 programs. The hold affects EBVALLO's treatment for EBV+ PTLD and ATA3219's therapy for non-Hodgkin's lymphoma and systemic lupus erythematosus.
The clinical hold stems from unresolved GMP compliance issues at a third-party manufacturing facility, which were previously identified in a Complete Response Letter (CRL) on January 16, 2025. While current participants showing potential clinical benefits may continue treatment, new enrollment has been paused.
The issues specifically affect one third-party facility and do not impact Atara's second manufacturer, FUJIFILM Diosynth Biotechnologies facility. Atara and FDA have agreed on necessary actions to release the holds, with FDA committing to work collaboratively for resolution.
Atara Biotherapeutics (NASDAQ: ATRA) received a Complete Response Letter (CRL) from the FDA regarding EBVALLO™ (tabelecleucel). The CRL solely relates to inspection findings at a third-party manufacturer and did not identify any issues with clinical efficacy, safety data, or manufacturing process. No new clinical trials were requested.
The company is working with Pierre Fabre Laboratories and the manufacturer to address the feedback and expects potential approval within six months of resubmission. EBVALLO, already approved in Europe, demonstrated a 50% Objective Response Rate in the pivotal ALLELE study.
Atara has secured a potential $15 million funding through an equity line of credit from Redmile Group to support BLA approval activities. The company reported approximately $43 million in cash and equivalents as of year-end 2024. Atara remains eligible for a $60 million milestone payment upon FDA approval and double-digit tiered royalties from Pierre Fabre.
Atara Biotherapeutics (Nasdaq: ATRA), a pioneer in T-cell immunotherapy focusing on EBV T-cell platform for cancer and autoimmune disease treatments, has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. Cokey Nguyen, Ph.D., President and CEO, will engage in a fireside chat on Tuesday, December 3, 2024, at 3:50 p.m. EST. The presentation will be accessible via live webcast in the Investors and Media section of atarabio.com, with a replay available for 30 days afterward.
Atara Biotherapeutics (Nasdaq: ATRA), a pioneer in T-cell immunotherapy focusing on EBV T-cell platform for cancer and autoimmune disease treatments, has announced its participation in the Stifel 2024 Healthcare Conference. Cokey Nguyen, Ph.D., President and CEO, will engage in a fireside chat on November 18, 2024 at 6:10 a.m. PST / 9:10 a.m. EST.
The presentation will be accessible via live webcast in the Investors and Media section of atarabio.com, with a replay available for 30 days after the event.
Atara Biotherapeutics (ATRA) reported Q3 2024 financial results and operational progress. The company's tab-cel® BLA is on track with a PDUFA date of January 15, 2025. Total revenues were $40.2 million, up from $2.1 million in Q3 2023. Net loss was $21.9 million ($2.93 per share). Cash position was $67.2 million as of September 30, 2024.
The company dosed its first patient in the ATA3219 Non-Hodgkin's Lymphoma study, with initial data expected Q1 2025. Atara expects to initiate studies for Lupus Nephritis and Extrarenal Systemic Lupus Erythematosus by year-end. The company projects its cash runway into 2027, supported by potential milestone payments and operational efficiencies.
Atara Biotherapeutics (Nasdaq: ATRA), a company specializing in T-cell immunotherapy and developing treatments for cancer and autoimmune diseases using its allogeneic Epstein-Barr virus (EBV) T-cell platform, has scheduled the release of its third quarter 2024 financial results. The results will be announced after market close on Tuesday, November 12, 2024.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, has reported the grant of 3,500 restricted stock units of its common stock to a newly hired employee. This award was approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of October 1, 2024.
The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date. The remainder vests in 12 approximately equal quarterly installments over the following three years, subject to continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement material to the new employee entering into employment with Atara.
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, has granted 3,700 restricted stock units to a newly hired employee. This inducement grant, approved by the Compensation Committee and made under the company's 2018 Inducement Plan, is in accordance with Nasdaq Listing Rule 5635(c)(4). The grant date is September 3, 2024.
The restricted stock units have a four-year vesting schedule: 25% vests on the first quarterly vesting date after the first anniversary, with the remaining 75% vesting in 12 approximately equal quarterly installments over the following three years. Vesting is subject to continuous employment with Atara.
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's Executive Vice President and Chief Scientific & Technical Officer, Cokey Nguyen, Ph.D., will present on Monday, September 9, 2024, at 6:30 a.m. PDT / 9:30 a.m. EDT.
Atara specializes in developing transformative therapies for patients with cancer and autoimmune diseases using its novel allogeneic Epstein-Barr virus (EBV) T-cell platform. Investors and interested parties can access a live webcast of the presentation through the Investors and Media section of atarabio.com. An archived replay will be available on the company's website for 30 days following the live presentation.
FAQ
What is the current stock price of Atara Biotherape (ATRA)?
What is the market cap of Atara Biotherape (ATRA)?
What does Atara Biotherapeutics, Inc specialize in?
When was Atara Biotherapeutics founded?
Who is Atara Ciechanover?
What are some of Atara's key product candidates?
With which institution is Atara Biotherapeutics collaborating?
What types of T-cell therapies is Atara developing?
What is the mission of Atara Biotherapeutics?
Where does Atara Biotherapeutics operate?
What are activin and myostatin in the context of Atara's research?
How does Atara manage its business operations?
